JP2016530213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530213A5 JP2016530213A5 JP2016515522A JP2016515522A JP2016530213A5 JP 2016530213 A5 JP2016530213 A5 JP 2016530213A5 JP 2016515522 A JP2016515522 A JP 2016515522A JP 2016515522 A JP2016515522 A JP 2016515522A JP 2016530213 A5 JP2016530213 A5 JP 2016530213A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- sulfonyl
- tetrahydroquinolin
- fluorophenyl
- hexafluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl Chemical group 0.000 claims 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 1
- RBEJZPHWOONGBK-UHFFFAOYSA-N 1-benzyl-3-[[1-(4-fluorophenyl)sulfonyl-6-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-3,4-dihydro-2H-quinolin-2-yl]methyl]urea Chemical compound OC(c1ccc2N(C(CNC(=O)NCc3ccccc3)CCc2c1)S(=O)(=O)c1ccc(F)cc1)(C(F)(F)F)C(F)(F)F RBEJZPHWOONGBK-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- MZFZBDFNAPJWGY-PIEWVDTRSA-N C(C)O\N=C(/C[C@H]1N(C2=CC=C(C=C2CC1)C(C(F)(F)F)(C(F)(F)F)O)S(=O)(=O)C1=CC=C(C=C1)F)\C Chemical compound C(C)O\N=C(/C[C@H]1N(C2=CC=C(C=C2CC1)C(C(F)(F)F)(C(F)(F)F)O)S(=O)(=O)C1=CC=C(C=C1)F)\C MZFZBDFNAPJWGY-PIEWVDTRSA-N 0.000 claims 1
- MZFZBDFNAPJWGY-NLQLCTRYSA-N C(C)O\N=C(\C[C@H]1N(C2=CC=C(C=C2CC1)C(C(F)(F)F)(C(F)(F)F)O)S(=O)(=O)C1=CC=C(C=C1)F)/C Chemical compound C(C)O\N=C(\C[C@H]1N(C2=CC=C(C=C2CC1)C(C(F)(F)F)(C(F)(F)F)O)S(=O)(=O)C1=CC=C(C=C1)F)/C MZFZBDFNAPJWGY-NLQLCTRYSA-N 0.000 claims 1
- JCAYOVKPNKUDOP-KQWLVTFDSA-N C1(=CC=CC=C1)O\N=C(\C[C@H]1N(C2=CC=C(C=C2CC1)C(C(F)(F)F)(C(F)(F)F)O)S(=O)(=O)C1=CC=C(C=C1)F)/C Chemical compound C1(=CC=CC=C1)O\N=C(\C[C@H]1N(C2=CC=C(C=C2CC1)C(C(F)(F)F)(C(F)(F)F)O)S(=O)(=O)C1=CC=C(C=C1)F)/C JCAYOVKPNKUDOP-KQWLVTFDSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- YYLNNBFDGZYCLZ-KRWDZBQOSA-N CC(C)(N)Cc1nnc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)o1 Chemical compound CC(C)(N)Cc1nnc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)o1 YYLNNBFDGZYCLZ-KRWDZBQOSA-N 0.000 claims 1
- LVYLRMXJXROXMH-INIZCTEOSA-N CC(C)(O)c1nnc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)o1 Chemical compound CC(C)(O)c1nnc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)o1 LVYLRMXJXROXMH-INIZCTEOSA-N 0.000 claims 1
- QDZCCHJOVLZIEY-BJQOMGFOSA-N CC(O)(CO)c1nnc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)o1 Chemical compound CC(O)(CO)c1nnc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)o1 QDZCCHJOVLZIEY-BJQOMGFOSA-N 0.000 claims 1
- QRVIJCNOXJMAQE-BGERDNNASA-N CCC(O)Cn1ccc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)n1 Chemical compound CCC(O)Cn1ccc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)n1 QRVIJCNOXJMAQE-BGERDNNASA-N 0.000 claims 1
- KOVFYSOWRLIZNN-HNNXBMFYSA-N CSc1nnc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)s1 Chemical compound CSc1nnc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)s1 KOVFYSOWRLIZNN-HNNXBMFYSA-N 0.000 claims 1
- ORUXJAJOWWWKDP-IBGZPJMESA-N FC(C(C(F)(F)F)(O)C=1C=C2CC[C@H](N(C2=CC=1)S(=O)(=O)C1=CC=C(C=C1)F)CC=1OC(=NN=1)C1=CC=NC=C1)(F)F Chemical compound FC(C(C(F)(F)F)(O)C=1C=C2CC[C@H](N(C2=CC=1)S(=O)(=O)C1=CC=C(C=C1)F)CC=1OC(=NN=1)C1=CC=NC=C1)(F)F ORUXJAJOWWWKDP-IBGZPJMESA-N 0.000 claims 1
- LCTMAKMOTSGICZ-UHFFFAOYSA-N FC1=CC=C(C=C1)S(=O)(=O)N1C(CCC2=CC(=CC=C12)C(C(F)(F)F)(C(F)(F)F)O)CNC(=O)NC1=CC=CC=C1 Chemical compound FC1=CC=C(C=C1)S(=O)(=O)N1C(CCC2=CC(=CC=C12)C(C(F)(F)F)(C(F)(F)F)O)CNC(=O)NC1=CC=CC=C1 LCTMAKMOTSGICZ-UHFFFAOYSA-N 0.000 claims 1
- QBLZQBOPZUOSEP-INIZCTEOSA-N FC1=CC=C(C=C1)S(=O)(=O)N1[C@@H](CCC2=CC(=CC=C12)C(C(F)(F)F)(C(F)(F)F)O)CC(=O)NNC(C(C)(C)O)=O Chemical compound FC1=CC=C(C=C1)S(=O)(=O)N1[C@@H](CCC2=CC(=CC=C12)C(C(F)(F)F)(C(F)(F)F)O)CC(=O)NNC(C(C)(C)O)=O QBLZQBOPZUOSEP-INIZCTEOSA-N 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- YVMCWBSJFQJLMS-INIZCTEOSA-N NC1(CC1)c1nnc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)o1 Chemical compound NC1(CC1)c1nnc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)o1 YVMCWBSJFQJLMS-INIZCTEOSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- GQGJVWYUFIORRZ-IBGZPJMESA-N OC(c1ccc2N([C@H](CC(=O)NNC(=O)c3ccncc3)CCc2c1)S(=O)(=O)c1ccc(F)cc1)(C(F)(F)F)C(F)(F)F Chemical compound OC(c1ccc2N([C@H](CC(=O)NNC(=O)c3ccncc3)CCc2c1)S(=O)(=O)c1ccc(F)cc1)(C(F)(F)F)C(F)(F)F GQGJVWYUFIORRZ-IBGZPJMESA-N 0.000 claims 1
- GTDXVWUKRLIACM-NRFANRHFSA-N OC(c1ccc2N([C@H](CNCc3ccccc3)CCc2c1)S(=O)(=O)c1ccc(F)cc1)(C(F)(F)F)C(F)(F)F Chemical compound OC(c1ccc2N([C@H](CNCc3ccccc3)CCc2c1)S(=O)(=O)c1ccc(F)cc1)(C(F)(F)F)C(F)(F)F GTDXVWUKRLIACM-NRFANRHFSA-N 0.000 claims 1
- MNHHBYVJYTWBGO-INIZCTEOSA-N OC(c1ccc2N([C@H](CNS(=O)(=O)C3CC3)CCc2c1)S(=O)(=O)c1ccc(F)cc1)(C(F)(F)F)C(F)(F)F Chemical compound OC(c1ccc2N([C@H](CNS(=O)(=O)C3CC3)CCc2c1)S(=O)(=O)c1ccc(F)cc1)(C(F)(F)F)C(F)(F)F MNHHBYVJYTWBGO-INIZCTEOSA-N 0.000 claims 1
- WPOUYVFYBNAPSI-DEOSSOPVSA-N OC(c1ccc2N([C@H](Cc3ccnn3Cc3ccc(F)cc3)CCc2c1)S(=O)(=O)c1ccc(F)cc1)(C(F)(F)F)C(F)(F)F Chemical compound OC(c1ccc2N([C@H](Cc3ccnn3Cc3ccc(F)cc3)CCc2c1)S(=O)(=O)c1ccc(F)cc1)(C(F)(F)F)C(F)(F)F WPOUYVFYBNAPSI-DEOSSOPVSA-N 0.000 claims 1
- YYGNTJLVXLCHGQ-BHWOMJMDSA-N OCC(O)Cc1nnc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)o1 Chemical compound OCC(O)Cc1nnc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)o1 YYGNTJLVXLCHGQ-BHWOMJMDSA-N 0.000 claims 1
- JJGIBUJPPDJWMM-XJDOXCRVSA-N OCC(O)Cn1ccc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)n1 Chemical compound OCC(O)Cn1ccc(C[C@@H]2CCc3cc(ccc3N2S(=O)(=O)c2ccc(F)cc2)C(O)(C(F)(F)F)C(F)(F)F)n1 JJGIBUJPPDJWMM-XJDOXCRVSA-N 0.000 claims 1
- HBNJOSMGIAZNMX-XJDOXCRVSA-N OCC(O)Cn1nccc1C[C@@H]1CCc2cc(ccc2N1S(=O)(=O)c1ccc(F)cc1)C(O)(C(F)(F)F)C(F)(F)F Chemical compound OCC(O)Cn1nccc1C[C@@H]1CCc2cc(ccc2N1S(=O)(=O)c1ccc(F)cc1)C(O)(C(F)(F)F)C(F)(F)F HBNJOSMGIAZNMX-XJDOXCRVSA-N 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- NKFLEFWUYAUDJV-UHFFFAOYSA-N pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CN=C1 NKFLEFWUYAUDJV-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361880391P | 2013-09-20 | 2013-09-20 | |
| US61/880,391 | 2013-09-20 | ||
| PCT/US2014/056197 WO2015042212A1 (en) | 2013-09-20 | 2014-09-18 | RORγ MODULATORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530213A JP2016530213A (ja) | 2016-09-29 |
| JP2016530213A5 true JP2016530213A5 (enExample) | 2017-10-26 |
| JP6397488B2 JP6397488B2 (ja) | 2018-09-26 |
Family
ID=51726859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515522A Expired - Fee Related JP6397488B2 (ja) | 2013-09-20 | 2014-09-18 | ＲＯＲγ調節因子 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9725443B2 (enExample) |
| EP (1) | EP3046906B1 (enExample) |
| JP (1) | JP6397488B2 (enExample) |
| CN (1) | CN105555768B (enExample) |
| WO (1) | WO2015042212A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3044219A1 (en) | 2013-09-09 | 2016-07-20 | Bristol-Myers Squibb Company | Rorgamma modulators |
| EP3046906B1 (en) | 2013-09-20 | 2017-08-16 | Bristol-Myers Squibb Company | Ror gamma modulators |
| WO2015090507A1 (en) * | 2013-12-19 | 2015-06-25 | Merck Patent Gmbh | Tetrahydro-tetrazolo[1,5-a]pyrazines as ror-gamma inhibitors |
| CN106061956B (zh) | 2014-01-06 | 2021-03-12 | 百时美施贵宝公司 | 作为RORγ调节剂的杂环砜 |
| US9708253B2 (en) | 2014-01-06 | 2017-07-18 | Bristol-Myers Squibb Company | Cyclohexyl sulfone RORγ modulators |
| EP3092216B1 (en) | 2014-01-06 | 2018-12-12 | Bristol-Myers Squibb Company | Carbocyclic sulfone ror gamma modulators |
| SMT201900706T1 (it) | 2014-10-30 | 2020-01-14 | Janssen Pharmaceutica Nv | Tiazoli sostituiti con ammide come modulatori di rorgammat |
| JOP20200117A1 (ar) | 2014-10-30 | 2017-06-16 | Janssen Pharmaceutica Nv | كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t |
| RS58250B1 (sr) | 2014-10-30 | 2019-03-29 | Janssen Pharmaceutica Nv | Tiazoli kao modulatori roryt |
| ES2887087T3 (es) * | 2015-05-07 | 2021-12-21 | Bristol Myers Squibb Co | Sulfonas tricíclicas como moduladores ROR gamma |
| TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| WO2017213210A1 (ja) * | 2016-06-10 | 2017-12-14 | 武田薬品工業株式会社 | 複素環化合物 |
| JP7083823B2 (ja) * | 2016-10-13 | 2022-06-13 | ブリストル－マイヤーズ スクイブ カンパニー | ＲＯＲγ修飾因子としてのヘテロ環スルホン類 |
| ES2928246T3 (es) | 2018-06-18 | 2022-11-16 | Janssen Pharmaceutica Nv | 6-aminopiridin-3-il pirazoles como moduladores de RORyt |
| JP2021527660A (ja) | 2018-06-18 | 2021-10-14 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγｔのモジュレータとしてのフェニル及びピリジニル置換イミダゾール |
| US10975037B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of RORγt |
| CN112292373A (zh) | 2018-06-18 | 2021-01-29 | 詹森药业有限公司 | 作为RORγt的调节剂的吡啶基吡唑类 |
| CN111635373B (zh) * | 2019-03-01 | 2022-07-12 | 山东轩竹医药科技有限公司 | 多环磺酰胺类RORγ调节剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20012060A1 (it) * | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | Nuovi eterocilcli n-acilati |
| US7741317B2 (en) * | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| EP2368886A1 (en) * | 2010-03-01 | 2011-09-28 | Phenex Pharmaceuticals AG | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease |
| CA2816753A1 (en) * | 2010-11-08 | 2012-05-18 | Lycera Corporation | N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases |
| WO2013064231A1 (en) * | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
| WO2014062938A1 (en) | 2012-10-19 | 2014-04-24 | Bristol-Myers Squibb Company | Rory modulators |
| EP3044219A1 (en) | 2013-09-09 | 2016-07-20 | Bristol-Myers Squibb Company | Rorgamma modulators |
| EP3046906B1 (en) | 2013-09-20 | 2017-08-16 | Bristol-Myers Squibb Company | Ror gamma modulators |
| KR101544975B1 (ko) * | 2013-09-30 | 2015-08-18 | 주식회사 플라즈마트 | 임피던스 매칭 방법 및 임피던스 매칭 시스템 |
| US9708253B2 (en) | 2014-01-06 | 2017-07-18 | Bristol-Myers Squibb Company | Cyclohexyl sulfone RORγ modulators |
| CN106061956B (zh) | 2014-01-06 | 2021-03-12 | 百时美施贵宝公司 | 作为RORγ调节剂的杂环砜 |
| CA2936116A1 (en) | 2014-01-06 | 2015-07-09 | Bristol-Myers Squibb Company | Pyrrolidinyl sulfone derivatives and their use as ror gamma modulators |
| EP3092216B1 (en) | 2014-01-06 | 2018-12-12 | Bristol-Myers Squibb Company | Carbocyclic sulfone ror gamma modulators |
-
2014
- 2014-09-18 EP EP14784387.4A patent/EP3046906B1/en not_active Not-in-force
- 2014-09-18 US US15/022,673 patent/US9725443B2/en active Active
- 2014-09-18 WO PCT/US2014/056197 patent/WO2015042212A1/en not_active Ceased
- 2014-09-18 JP JP2016515522A patent/JP6397488B2/ja not_active Expired - Fee Related
- 2014-09-18 CN CN201480051836.2A patent/CN105555768B/zh not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530213A5 (enExample) | ||
| JP2011521911A5 (enExample) | ||
| JP2016505637A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2017508782A5 (enExample) | ||
| JP2016515582A5 (enExample) | ||
| JP2017501237A5 (enExample) | ||
| JP2014510132A5 (enExample) | ||
| JP2014526501A5 (enExample) | ||
| JP2012041349A5 (enExample) | ||
| JP2018516904A5 (enExample) | ||
| JP2014526500A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2015520769A5 (enExample) | ||
| JP2012140432A5 (enExample) | ||
| JP2012530705A5 (enExample) | ||
| JP2011502958A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2019504050A5 (enExample) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2017525737A5 (enExample) | ||
| RU2014148316A (ru) | Производные 1-фенил-2-пиридинил-алкиловых спиртов в качестве ингибиторов фосфодиэстеразы |